Reunion Neuroscience Inc
Change company Symbol lookup
Select an option...
REUN Reunion Neuroscience Inc
CRT Cross Timbers Royalty Trust
ABBV Abbvie Inc
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
Go

Health Care : Health Care Providers & Services | Small Cap Growth
Based in Canada
Company profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Closing Price
$1.23
Day's Change
-0.08 (-6.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.34
Day's Low
1.23
Volume
(Light)
Volume:
5,838

10-day average volume:
14,154
5,838
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.